An exploratory study of changes in synovial immune responses following BMS-188667 [abatacept] therapy in subjects with active rheumatoid arthritis on background DMARDs [disease-modifying anti-rheumatic drugs] who have failed anti-TNF [tumour-necrosis-factor-antagonists] therapy.

Trial Profile

An exploratory study of changes in synovial immune responses following BMS-188667 [abatacept] therapy in subjects with active rheumatoid arthritis on background DMARDs [disease-modifying anti-rheumatic drugs] who have failed anti-TNF [tumour-necrosis-factor-antagonists] therapy.

Completed
Phase of Trial: Phase I

Latest Information Update: 16 Jan 2017

At a glance

  • Drugs Abatacept (Primary)
  • Indications Rheumatoid arthritis
  • Focus Biomarker; Pharmacodynamics
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 02 Nov 2006 Status change
    • 10 Feb 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top